PET Ligand GE-180 Cleared for Testing to Assess Inflammation in Neurodegenerative Disease

Cleveland Clinic IND application is first approved in Parkinson’s and Alzheimer’s

Cleveland Clinic Lou Ruvo Center for Brain Health has received FDA approval of its Investigational New Drug (IND) application to test the GE-180 ligand tracer in the brains of individuals with Parkinson’s disease and Alzheimer’s disease.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

The novel tracer will be used in a PET imaging investigation to assess neuroinflammation in the brains of 70 study participants with normal cognitive function or either Parkinson’s or Alzheimer’s disease, with the aim of elucidating links between inflammation and neurodegeneration. The IND makes the Lou Ruvo Center for Brain Health the first trial site testing GE-180 in these patient populations.

While researchers increasingly report findings suggestive of an important role for neuroinflammation in the pathology of neurodegenerative conditions, more research is warranted, particularly in the living brain. Ligand tracers such as GE-180 are used to help better depict protein interactions in living cells.

“We know there is some connection between inflammation and neurodegenerative disease, but we have yet to confirm what it is,” explains principal investigator Aaron Ritter, MD, Director of the Clinical Trials Program at the Lou Ruvo Center for Brain Health, who holds the IND for the GE-180 study. “Until now, it has been hard to quantify in a living brain. The GE-180 tracer is an exciting opportunity to contribute to the science of brain disease in ways that have not previously been studied.”

Advertising Policy

He adds: “If we can confirm that inflammation plays a role in dementia, this could lead to new treatments that specifically target cognitive decline.”

The two-year imaging investigation is an observational substudy of the Lou Ruvo Center for Brain Health’s Center of Biomedical Research of Excellence (COBRE) grant, which aims to understand the similarities between Parkinson’s and Alzheimer’s diseases. The COBRE grant is funded by Institutional Development Award (IDeA) P20GM109025 from the National Institutes of Health.

Image credit: U.S. National Institute on Aging